Panagora Asset Management Inc. Decreases Stock Holdings in Boston Scientific Corporation $BSX

Panagora Asset Management Inc. reduced its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 39.9% during the second quarter, HoldingsChannel.com reports. The fund owned 667,889 shares of the medical equipment provider’s stock after selling 443,488 shares during the quarter. Panagora Asset Management Inc.’s holdings in Boston Scientific were worth $71,738,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently made changes to their positions in the company. GAMMA Investing LLC increased its stake in shares of Boston Scientific by 15.4% in the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after purchasing an additional 3,932 shares in the last quarter. MRA Advisory Group purchased a new position in Boston Scientific in the 2nd quarter valued at approximately $273,000. Bank of New Hampshire raised its holdings in Boston Scientific by 552.0% during the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock valued at $2,119,000 after acquiring an additional 16,699 shares during the period. NS Partners Ltd lifted its position in shares of Boston Scientific by 1.6% during the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock worth $37,143,000 after acquiring an additional 5,704 shares in the last quarter. Finally, New England Research & Management Inc. bought a new position in shares of Boston Scientific in the second quarter worth $1,133,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Trading Up 1.0%

NYSE:BSX opened at $101.95 on Monday. The firm has a market capitalization of $151.13 billion, a P/E ratio of 54.52, a P/E/G ratio of 2.02 and a beta of 0.58. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The company has a fifty day moving average of $99.17 and a 200 day moving average of $102.27. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, research analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

BSX has been the topic of a number of recent research reports. Robert W. Baird increased their price objective on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Morgan Stanley upped their target price on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Royal Bank Of Canada reissued an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a report on Monday, September 29th. BTIG Research reissued a “buy” rating and issued a $132.00 price target on shares of Boston Scientific in a research note on Friday, November 21st. Finally, Truist Financial raised their price objective on shares of Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $123.77.

Insider Activity at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,561,336.74. The trade was a 21.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 175,782 shares of company stock worth $17,742,314 over the last three months. Insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.